METXF
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, whic… Read more
METXF (METXF) - Total Assets
Latest total assets as of November 2025: $1.55 Million USD
Based on the latest financial reports, METXF (METXF) holds total assets worth $1.55 Million USD as of November 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
METXF - Total Assets Trend (2022–2025)
This chart illustrates how METXF’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
METXF - Asset Composition Analysis
Current Asset Composition (August 2025)
METXF's total assets of $1.55 Million consist of 85.4% current assets and 14.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 76.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how METXF's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: METXF's current assets represent 85.4% of total assets in 2025, a decrease from 100.0% in 2022.
- Cash Position: Cash and equivalents constituted 76.5% of total assets in 2025, down from 100.0% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
METXF Competitors by Total Assets
Key competitors of METXF based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
METXF - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - METXF generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - METXF is currently not profitable relative to its asset base.
METXF - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.99 | 8.18 | 5.42 |
| Quick Ratio | 5.99 | 8.18 | 5.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.10 Million | $ 1.26 Million | $ 522.38K |
METXF - Advanced Valuation Insights
This section examines the relationship between METXF's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 90.33 |
| Latest Market Cap to Assets Ratio | 28.15 |
| Asset Growth Rate (YoY) | 14.3% |
| Total Assets | $1.76 Million |
| Market Capitalization | $49.53 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values METXF's assets at a significant premium ( 28.15x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: METXF's assets grew by 14.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for METXF (2022–2025)
The table below shows the annual total assets of METXF from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-08-31 | $1.76 Million | +14.35% |
| 2024-08-31 | $1.54 Million | +129.01% |
| 2023-08-31 | $671.86K | +68.85% |
| 2022-08-31 | $397.91K | -- |